PubMed Health⌕ Search
Home/Archive/PubMed

PubMed · 8826749

Dysosteosclerosis.

E John·K Kozlowski·J Masel·S Muralinath·G Vijayalakshmi
View original source ↗Export metadata ↓

Abstract

A 5 1/2 year old boy presented with delayed development and loss of vision. A skeletal survey showed osteosclerosis consistent with dysosteosclerosis. Some unusual features of dysosteosclerosis are discussed.

Explore related subjects

Bone and BonesChild, PreschoolGenes, RecessiveHumansLumbar VertebraeMaleOsteosclerosisRadiographyThoracic VertebraeCase ReportsJournal Article

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

E John, K Kozlowski, J Masel, S Muralinath, G Vijayalakshmi. 1996. Dysosteosclerosis.. https://doi.org/10.1111/j.1440-1673.1996.tb00417.x

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed1999

Raloxifene: a selective estrogen receptor modulator.

Raloxifene is a selective estrogen receptor modulator that produces both estrogen-agonistic effects on bone and lipid metabolism and estrogen-antagonistic effects on uterine endometrium and breast tissue. Because of its tissue selectivity, raloxifene may have fewer side effects than are typically observed with estrogen therapy. The most common adverse effects of raloxifene are hot flushes and leg cramps. The drug is also associated with an increased risk of thromboembolic events. The beneficial estrogenic activities of raloxifene include a lowering of total and low-density lipoprotein cholesterol levels and an augmentation of bone mineral density. Raloxifene has been labeled by the U.S. Food and Drug Administration for the prevention of osteoporosis. However, its effects on fracture risk and its ability to protect against cardiovascular disease have yet to be determined. Studies are also being conducted to determine its impact on breast and endometrial cancer reduction.

Bone and Bones↗